• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

Opinion
Video

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

Video content above is prompted by the following:

  • Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (Abstract)

1. What was the objective of this study?

2. How was this study designed/what methodology was used?

3. What results were presented?

i. Patient population: N=46

A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors

ii. Primary objectives:

A. Safety

B. Selection of recommended dose

iii. Secondary objectives:

A. Efficacy

B. ctDNA response

  • Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
4 KOLs are featured in this series
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.